Systematic Literature Review and Mixed Treatment Comparison of Gxr Versus other Treatments in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
Open accessIntegrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Previous network meta-analyses in ADHD have focused on either children and adolescents or adults only, have typically compared only a few drugs, or have addressed exclusively the safety of treatments.
“Previous network meta-analyses in ADHD have focused on either children and adolescents19, 20, 21, 22, 23, 24 or adults only,25, 26, 27, 28 have typically compared only a few drugs,24, 25, 27, 29 or have addressed exclusively the safety of treatments.26”
We have addressed limitations of previous network meta-analyses, which focused selectively on children and adolescents or adults, or included only published material, non-blinded trials, or non-core ADHD outcomes.
“We have addressed the limitations of previous network meta-analyses, which focused selectively on children and adolescents19, 20, 21, 22, 23, 24 or adults,25, 26, 27, 28 or included only published material,21, 22, 23, 24, 26 non-blinded trials,19, 21, 22, 23, 24 or non-core ADHD outcomes.19, 22, 25, 28”
Cited by
Sorted by citations
Cortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A. J., Carucci, S., Atkinson, L. Z., Tessari, L., Banaschewski, T., Coghill, D., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30269-4 · Cited by 1,402 · see citing works
- Authors
- Joseph, A., Ayyagari, R., Bischof, M., Cai, S., Xie, M., Zhanabekova, Z., & Sikirica, V.
- Affiliations
- Shire (Switzerland) (CH)
- Analysis Group (United States) (US)
- Venue
- Value in Health
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 17
- Issue
- 7
- Pages
- A454
- ISSN
- 1098-3015 (ISSN-L)
- OpenAlex
- W2065199880
- Cited by
- 4
- References
- 0
- Citations by year
- 2023: 1 · 2018: 2 · 2016: 1
- FWCI
- 0.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Value in Health (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- guanfacine, atomoxetine, lisdexamfetamine, methylphenidate, attention deficit hyperactivity disorder, children and adolescents, ADHD treatment efficacy, non-stimulant medication, stimulant medication, ADHD-RS-IV, sustained-release formulation, placebo response, age and sex effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
